Plenaxis (abarelix), a new drug for advanced prostate cancer

January 2004

Some men will be put on Plenaxis (abarelix), a new drug for advanced prostate cancer.

Plenaxis suppresses testosterone by blocking gonadotropin- releasing hormone receptors. It doesn't cause an initial testosterone surge...like Lupron and other gonadotropin agonists.

But Plenaxis has a serious drawback...it causes life-threatening allergic reactions in almost 4% of patients.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

alternatives to prevent or treat flu
Cardiology Spironolactone will be used more for hypertension
Diabetes More people will be labeled as having "pre-diabetes"
A simple new technique might help patients who get nosebleeds from nasal steroids
single-ingredient, extended-release guaifenesin products
Men's Health some medications can worsen urinary symptoms
Hematology & Oncology potential interaction between tamoxifen and paroxetine (Paxil)
Hematology & Oncology Plenaxis (abarelix), a new drug for advanced prostate cancer
Bipolar Disorder Risperdal (risperidone) is now approved for acute mania
Obesity & Weight Loss what works for weight loss
Women's Health More women will use emergency contraceptives
Women's Health Climara Pro, a new COMBINATION estrogen and progestin patch for relieving menopausal symptoms
More frequent lab tests will be recommended for rheumatoid arthritis patients taking Arava (leflunomide)
FLUIDjoint, a new supplement for osteoarthritis
Medicare The big changes to Medicare will affect your practice

Plenaxis (abarelix), a new drug for advanced prostate cancer

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents